title: Carcinogenicity of the antineoplastic agent, 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide, and its metabolites in rats.
abstract: Chronic oral administration of the antineoplastic agent, 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388, DTIC), induced predominantly thymic and mammary tumors as demonstrated previously. Male and female Sprague-Dawley and female Buffalo rats were susceptible to the carcinogenicity of DTIC. A 50% incidence of mammary adenocarcinomas was induced in males within 18 weeks. Type of tumor and tumor incidence were dose dependent. Single and multiple intraperitoneal injections of DTIC did not alter organ specificity. DTIC-induced thymic lymphosarcomas and mammary adenocarcinomas were transplantable. Tissue distribution studies revealed no correlation between uptake of DTIC by a given tissue and its susceptibility to carcinogenicity. Metabolites of DTIC were tested for carcinogenic activity. Animals administered 5-diazoimidazole-4-carboxamide orally, intraperitoneally, or intragastrically developed low incidences of thymic, stomach, bladder, or mammary tumors. A low incidence of mammary tumors developed in rats fed 2-azahypoxanthine. A variety of tumors, including several ependymoblastomas, were induced in rats that received 5-aminoimidazole-4-carboxamide orally. 5-(3-Methyl-1-triazeno)imidazole-4-carboxamide (MTIC), when fed or given in single or multiple intraperitoneal injections, induced a high incidence of mammary adenofibromas and a low incidence of uterine leiomyosarcomas. Control rats had low incidences of mammary adenocarcinomas and adenofibromas after 52 weeks. These data show that the carcinogenic properties of DTIC resemble those of carcinogenic N-nitroso compounds, hydrazine, azo, and azoxy-alkanes and aryltriazenes and thus suggest similar mechanism(s) of action. These data also indicate that MTIC is involved in the induction of mammary adenofibromas and uterine leiomyosarcomas by DTIC.
mesh_terms: D000232:Adenofibroma / Q000139:chemically induced; D000284:Administration, Oral; D000818:Animals; D001372:Aza Compounds / Q000633:toxicity; D002273:Carcinogens; D003606:Dacarbazine / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004806:Ependymoma / Q000139:chemically induced; D005260:Female; D007042:Hypoxanthines / Q000633:toxicity; D007274:Injections, Intraperitoneal; D007441:Intubation, Gastrointestinal; D007890:Leiomyosarcoma / Q000139:chemically induced; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced; D009374:Neoplasms, Experimental / Q000139:chemically induced*; D009928:Organ Specificity; D051381:Rats; D013274:Stomach Neoplasms / Q000139:chemically induced; D013953:Thymus Neoplasms / Q000139:chemically induced; D013997:Time Factors; D014226:Triazenes / Q000633:toxicity*; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced; D014594:Uterine Neoplasms / Q000139:chemically induced
chemical_list: D001372:Aza Compounds; D002273:Carcinogens; D007042:Hypoxanthines; D014226:Triazenes; D003606:Dacarbazine